We identify kinase inhibitors and epigenome modifiers (e.g., BET inhibitors) that appear to block acquisition of the slowly cycling NGFRHigh state in cell lines and in a BRAFV600E melanoma xenograft model and thereby increase sensitivity to vemurafenib. The gene discussed is DNER; the disease is melanoma.